What is Phi Pharma?
Phi Pharma is a biopharmaceutical company focused on pioneering Peptide Drug Conjugate (PDC) technology to revolutionize cancer treatment. Their proprietary platform is engineered to target the Chondroitin-Sulfate Proteoglycan-4 (CSPG4) antigen, a challenging target for conventional antibody-based therapies. The company's strategic approach involves developing potent PDCs for both solid and liquid tumors that exhibit high CSPG4 expression, leveraging deep expertise in hematology and oncology to advance its therapeutic pipeline.
How much funding has Phi Pharma raised?
Phi Pharma has raised a total of $3.6M across 1 funding round:
Series A
$3.6M
Series A (2016): $3.6M, investors not publicly disclosed
What's next for Phi Pharma?
The substantial enterprise-level funding positions Phi Pharma for accelerated pipeline development and clinical progression. This strategic investment is expected to fuel the expansion of their PDC therapies across various cancer indications, potentially marking a new era in targeted oncology treatments. The company's focus on a difficult-to-target antigen suggests a commitment to addressing unmet medical needs in aggressive cancers.
See full Phi Pharma company page
